Discover how TPD52, a novel prostate cancer vaccine target, is revolutionizing cancer immunotherapy through precision immune system training.
A groundbreaking clinical trial explores a vaccine to prevent prostate cancer recurrence by harnessing the power of the body's own defenses.
Exploring how arginine deprivation therapy exploits autophagy's dual role in prostate cancer treatment using ADI-PEG20